# Dr. Hance Clarke on The Medical Cannabis Real-World Evidence Study &amp; Catherine Iniss &#8230;

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/dr-hance-clarke-on-the-medical-cannabis-real-world-evidence-study-catherine-iniss/
> **Published:** 2026-06-18T07:10:46-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:22:40-04:00
> **Clinical Summary:** Dr. Hance Clarke's cannabis real-world evidence study bridges research and practice, documenting effectiveness in diverse patient populations.

---

✦ New

CED Clinical Relevance
#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.

ResearchPainAnxietySleepSafetyPolicy[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)

Clinical Summary

# Clinical Summary

The University Health Network is initiating a real-world evidence study to systematically evaluate [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) efficacy for specific clinical conditions, addressing a significant gap in the clinical literature where regulatory approval has outpaced rigorous evidence generation. Real-world evidence studies track patient outcomes in actual [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) settings rather than controlled trials, providing practical data on effectiveness, safety, and optimal dosing across diverse patient populations and comorbidities. This research approach is particularly valuable for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), where heterogeneous patient populations, variable product formulations, and inconsistent dosing regimens have complicated evidence-based practice. By generating robust clinical data on conditions where patients are already using cannabis therapeutically, researchers can help clinicians distinguish between anecdotal benefit and evidence-supported indications, thereby improving prescribing confidence and patient outcomes. For clinicians, this study offers the opportunity to contribute clinical observations to a structured database while gaining access to emerging evidence on efficacy and safety profiles. Physicians should anticipate that real-world evidence from this study may refine clinical guidance on [cannabis dosing](https://cedclinic.com/medical-cannabis-safety-facts/), strain selection, and appropriate patient populations, ultimately supporting more informed clinical decision-making.

Dr. Caplan’s Take
“The real-world evidence we’re gathering through studies like this is valuable because it captures how cannabis actually performs in [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) rather than under tightly controlled conditions, but we need to be clear that observational data tells us what’s happening, not necessarily why it’s happening or whether we’re seeing true efficacy or confounding effects. What gets me excited is when we can eventually link these real-world patterns to rigorous randomized trials, because that’s where we can actually inform clinical decision-making with confidence.”

Clinical Perspective

💊 While real-world evidence studies on [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) can provide valuable insights into clinical outcomes outside rigorous trial conditions, healthcare providers should interpret such data with appropriate caution, as observational designs are susceptible to selection bias, placebo effects, and confounding by indication that are difficult to fully control. The emerging evidence from academic health networks like the University Health Network helps address the substantial knowledge gap regarding cannabis efficacy for specific conditions, yet heterogeneity in cannabis products, dosing, administration routes, and patient populations across real-world studies limits generalizability to individual clinical decisions. Clinicians should remain aware that regulatory frameworks and available evidence differ significantly across jurisdictions, and that many patients are already using cannabis regardless of guideline status, creating a clinical reality where informed shared decision-making becomes essential. Given these complexities, the most practical approach is to systematically document patient-reported outcomes when cannabis is used, maintain awareness of emerging trial data, and counsel patients

💬 Join the Conversation

Have a question about how this applies to your situation?
[Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers?
[Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/)

Have thoughts on this? Share it:

[X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Dr.%20Hance%20Clarke%20on%20The%20Medical%20Cannabis%20Real-World%20Evidence%20Study%20%26amp%3B%20Catherine%20Iniss%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59542)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59542)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Dr.%20Hance%20Clarke%20on%20The%20Medical%20Cannabis%20Real-World%20Evidence%20Study%20%26amp%3B%20Catherine%20Iniss%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59542)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

📰 Source: [https://music.amazon.co.uk/podcasts/ad8d4f71-7cb6-443d-8fad-dcf2b5caf64f/episodes/c3069e6d-d487-448e-ba3f-512deb2850f3/zoomer-week-in-review-dr-hance-clarke-on-the-medical-cannabis-real-world-evidence-study-catherine-iniss-on-cottage-properties](https://music.amazon.co.uk/podcasts/ad8d4f71-7cb6-443d-8fad-dcf2b5caf64f/episodes/c3069e6d-d487-448e-ba3f-512deb2850f3/zoomer-week-in-review-dr-hance-clarke-on-the-medical-cannabis-real-world-evidence-study-catherine-iniss-on-cottage-properties)

Further Reading
CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/)
Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/)
CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
